NEW
YORK, June 27, 2024 /PRNewswire/ -- The
global diffuse large B-cell lymphoma (DLBCL) therapeutics
market size is estimated to grow by USD
2.24 billion from 2024-2028, according to Technavio.
The market is estimated to grow at a CAGR of 8.09% during the
forecast period. Growing geriatric population is driving market
growth, with a trend towards technological advances. However,
cytotoxicity of drugs and inclination toward radiation treatments
poses a challenge. Key market players include AbbVie Inc., ADC
Therapeutics SA, Amgen Inc., Bayer AG, BeiGene Ltd., Bristol Myers
Squibb Co., Celltrion Healthcare Co. Ltd., CTI BioPharma Corp.,
Erytech Pharma SA, F. Hoffmann La Roche Ltd., Gilead Sciences Inc.,
GlaxoSmithKline Plc, Johnson and Johnson Services Inc., Merck and
Co. Inc., Novartis AG, Pfizer Inc., Seagen Inc., Spectrum
Pharmaceuticals Inc., Takeda Pharmaceutical Co. Ltd., and Teva
Pharmaceutical Industries Ltd..
Get a detailed analysis on regions, market
segments, customer landscape, and companies- View the
snapshot of this report
Diffuse Large B-Cell
Lymphoma (Dlbcl) Therapeutics Market Scope
|
Report
Coverage
|
Details
|
Base year
|
2023
|
Historic
period
|
2018 - 2022
|
Forecast
period
|
2024-2028
|
Growth momentum &
CAGR
|
Accelerate at a CAGR of
8.09%
|
Market growth
2024-2028
|
USD 2249.8
million
|
Market
structure
|
Fragmented
|
YoY growth 2022-2023
(%)
|
7.32
|
Regional
analysis
|
North America, Europe,
Asia, and Rest of World (ROW)
|
Performing market
contribution
|
North America at
47%
|
Key
countries
|
US, Germany, UK,
Canada, and China
|
Key companies
profiled
|
AbbVie Inc., ADC
Therapeutics SA, Amgen Inc., Bayer AG, BeiGene Ltd., Bristol Myers
Squibb Co., Celltrion Healthcare Co. Ltd., CTI BioPharma Corp.,
Erytech Pharma SA, F. Hoffmann La Roche Ltd., Gilead Sciences Inc.,
GlaxoSmithKline Plc, Johnson and Johnson Services Inc., Merck and
Co. Inc., Novartis AG, Pfizer Inc., Seagen Inc., Spectrum
Pharmaceuticals Inc., Takeda Pharmaceutical Co. Ltd., and Teva
Pharmaceutical Industries Ltd.
|
Market Driver
The DLBCL therapeutics market is witnessing significant
advancements with companies investing in new technologies and
innovative therapies. Notable developments include chimeric antigen
receptor (CAR) T-cell therapy and gene therapy. Novartis and Gilead
are key industry players focusing on CAR T-cell therapy, with
Yescarta and Kymriah being notable examples. These therapies offer
more effective treatments, reduce efforts, and align with
individual patient needs. Gene therapy is another promising area,
with industry-focused and diversified players making strides.
Overall, these technological advances are enhancing treatment
efficacy and shaping the DLBCL therapeutics market.
The Diffuse Large B-Cell Lymphoma (DLBCL) therapeutics market is
currently experiencing significant growth due to the increasing
number of diagnosed cases and the development of new treatment
options. Chemotherapy, such as Rituximab, CHOP, and DLCBL, remains
a common treatment method. However, new technologies like CAR-T
cell therapy from companies like Novartis and Gilead Sciences are
gaining popularity. These innovative treatments offer longer
remission periods and improved patient outcomes. Additionally,
monoclonal antibodies like Ibrutinib and Idelalisib are making a
mark in the market with their ability to target specific proteins
in DLBCL cells. The market is expected to continue growing as
research and development efforts focus on enhancing treatment
efficacy and reducing side effects.
Research report provides comprehensive data on
impact of trend. For more details- Download a Sample
Report
Market Challenges
- The DLBCL therapeutics market experiences moderate growth due
to the use of cytotoxic drugs like vincristine, doxorubicin, and
carboplatin, which have adverse side effects and impact normal
cells. Radiation therapy, another treatment option, also presents
side effects. However, research and development efforts aim to
reduce these side effects and create innovative drugs, fostering
market growth.
- The Diffuse Large B-Cell Lymphoma (DLBCL) therapeutics market
faces several challenges in providing effective treatments.
Chemotherapy, such as Rituximab, is a common treatment, but drug
resistance is a significant issue. Inhibitors like Bruton's
Tyrosine Kinase (BTK) and Syk are being explored to address this
challenge. However, the high cost of these advanced therapies is a
major concern for patients and healthcare systems. Additionally,
the need for long-term treatment and potential side effects can
impact patient compliance. The market requires innovative solutions
to improve treatment efficacy, reduce costs, and enhance patient
experience.
For more insights on driver and
challenges - Request a sample report!
Segment Overview
This diffuse large b-cell lymphoma (dlbcl) therapeutics market
report extensively covers market segmentation by
- Application
- 1.1 Hospital pharmacy
- 1.2 Retail pharmacy
- 1.3 Online pharmacy
- 1.4 Others
- Product
- 2.1 Small molecules
- 2.2 Biologics
- Geography
- 3.1 North America
- 3.2 Europe
- 3.3 Asia
- 3.4 Rest of World (ROW)
1.1 Hospital pharmacy- Hospital pharmacies are
essential in DLBCL treatment, managing storage, preparation, and
dispensing of DLBCL therapeutics. Pharmacists oversee patient care,
monitoring adverse effects and drug interactions. Education on
medication use and collaboration with healthcare providers ensure
optimal care. The hospital pharmacy segment significantly
contributes to the DLBCL therapeutics market's growth due to the
hospital-based administration of these treatments. Ensuring safe
and effective use of DLBCL therapeutics is the primary role of
hospital pharmacies and pharmacists.
For more information on market segmentation with geographical
analysis including forecast (2024-2028) and historic data
(2017-2021) - Download a Sample Report
Research Analysis
The Diffuse Large B-Cell Lymphoma (DLBCL) therapeutics market
encompasses a range of innovative treatments for this type of
hematologic malignancy. Key therapeutic classes include monoclonal
antibodies, such as Rituximab, and kinase inhibitors, like
Ibrutinib. These targeted therapies have revolutionized the
treatment landscape for DLBCL, providing effective options for
patients with marginal zone lymphoma, Mantle cell lymphoma, Small
lymphocytic lymphoma, Chronic lymphocytic leukemia, and Waldenstrom
macroglobulinemia. Immunomodulatory drugs, such as Liso-cel, also
play a significant role in DLBCL treatment. Advanced therapies,
like GOLCA and CAR-T cell therapies, are under investigation and
hold promise for future developments. Treatment regimens, such as
R-CHOP, are commonly used in combination with these targeted
therapies to improve patient outcomes. Newer therapies, like
Zilovertamab vedotin, are also being explored to address the unmet
needs in DLBCL treatment. These therapies target specific proteins,
such as BTK and SYK, to inhibit the growth and proliferation of
malignant B-cells in lymph nodes and other affected sites,
including the thymus.
Market Research Overview
The Diffuse Large B-Cell Lymphoma (DLBCL) Therapeutics Market
encompasses innovative treatments and therapies designed to address
this type of cancer. Drugs and treatments under development aim to
target specific cellular markers and pathways, such as CD20, BCL-2,
and CHOP. Monoclonal antibodies, chemotherapies, and
immunomodulatory agents are among the therapeutic categories being
explored. Nucleic acids, enzymes, and targeted therapies are also
being investigated. The market is driven by the increasing
incidence of DLBCL and the need for more effective and less toxic
treatment options. The goal is to improve patient outcomes and
survival rates through the development of new and improved
therapies. The market is expected to grow significantly due to the
increasing demand for advanced treatments and the ongoing research
and development efforts in this field.
Table of Contents:
1 Executive Summary
2 Market Landscape
3 Market Sizing
4 Historic Market Size
5 Five Forces Analysis
6 Market Segmentation
- Application
-
- Hospital Pharmacy
- Retail Pharmacy
- Online Pharmacy
- Others
- Product
-
- Small Molecules
- Biologics
- Geography
-
- North America
- Europe
- Asia
- Rest Of World (ROW)
7 Customer Landscape
8 Geographic Landscape
9 Drivers, Challenges, and Trends
10 Company Landscape
11 Company Analysis
12 Appendix
About Technavio
Technavio is a leading global technology research and advisory
company. Their research and analysis focuses on emerging market
trends and provides actionable insights to help businesses identify
market opportunities and develop effective strategies to optimize
their market positions.
With over 500 specialized analysts, Technavio's report library
consists of more than 17,000 reports and counting, covering 800
technologies, spanning across 50 countries. Their client base
consists of enterprises of all sizes, including more than 100
Fortune 500 companies. This growing client base relies on
Technavio's comprehensive coverage, extensive research, and
actionable market insights to identify opportunities in existing
and potential markets and assess their competitive positions within
changing market scenarios.
Contacts
Technavio Research
Jesse Maida
Media & Marketing Executive
US: +1 844 364 1100
UK: +44 203 893 3200
Email: media@technavio.com
Website: www.technavio.com/
View original content to download
multimedia:https://www.prnewswire.com/news-releases/diffuse-large-b-cell-lymphoma-dlbcl-therapeutics-market-size-is-set-to-grow-by-usd-2-24-billion-from-2024-2028--growing-geriatric-population-boost-the-market-technavio-302183523.html
SOURCE Technavio